168 related articles for article (PubMed ID: 10882031)
1. Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
Matthes J; Huber I; Haaf O; Antepohl W; Striessnig J; Herzig S
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):578-83. PubMed ID: 10882031
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model.
Griffin KA; Picken M; Bakris GL; Bidani AK
Hypertension; 2001 May; 37(5):1268-72. PubMed ID: 11358939
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Min JY; Sandmann S; Meissner A; Unger T; Simon R
J Pharmacol Exp Ther; 1999 Dec; 291(3):1038-44. PubMed ID: 10565822
[TBL] [Abstract][Full Text] [Related]
4. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Baylis C; Qiu C; Engels K
Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
[TBL] [Abstract][Full Text] [Related]
5. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.
Eller P; Berjukov S; Wanner S; Huber I; Hering S; Knaus HG; Toth G; Kimball SD; Striessnig J
Br J Pharmacol; 2000 Jun; 130(3):669-77. PubMed ID: 10821797
[TBL] [Abstract][Full Text] [Related]
6. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.
Salomone S; Godfraind T
Br J Pharmacol; 1993 May; 109(1):100-6. PubMed ID: 8495233
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Sandmann S; Claas R; Cleutjens JP; Daemen MJ; Unger T
J Cardiovasc Pharmacol; 2001 Jan; 37(1):64-77. PubMed ID: 11152376
[TBL] [Abstract][Full Text] [Related]
8. Residual inhibition in density of [3H]isradipine binding sites in rat brain membrane pretreated with amlodipine.
Qu YL; Takamizawa C; Sugiyama K; Maruyama K; Hattori K; Watanabe K; Nagatomo T
Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):289-93. PubMed ID: 7668092
[TBL] [Abstract][Full Text] [Related]
9. The block of the expressed L-type calcium channel is modulated by the beta 3 subunit.
Lacinová L; Ludwig A; Bosse E; Flockerzi V; Hofmann F
FEBS Lett; 1995 Oct; 373(2):103-7. PubMed ID: 7589444
[TBL] [Abstract][Full Text] [Related]
10. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats.
Wagner C; Krämer BK; Hinder M; Kieninger M; Kurtz A
Br J Pharmacol; 1998 Jun; 124(3):579-85. PubMed ID: 9647484
[TBL] [Abstract][Full Text] [Related]
11. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine.
Segawa D; Sjöquist PO; Nordlander M; Wang QD; Gonon A; Rydén L
Eur J Pharmacol; 1999 Sep; 380(2-3):123-8. PubMed ID: 10513571
[TBL] [Abstract][Full Text] [Related]
12. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site.
Kwan YW; Bangalore R; Lakitsh M; Glossmann H; Kass RS
J Mol Cell Cardiol; 1995 Jan; 27(1):253-62. PubMed ID: 7760349
[TBL] [Abstract][Full Text] [Related]
14. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
Karam H; Clozel JP; Bruneval P; Gonzalez MF; Ménard J
Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
Ma G; Allen TJ; Cooper ME; Cao Z
Kidney Int; 2004 Sep; 66(3):1090-8. PubMed ID: 15327403
[TBL] [Abstract][Full Text] [Related]
16. Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967).
Avdonin PV; Buhler FR; Tkachuk VA
Membr Cell Biol; 2000; 13(5):645-55. PubMed ID: 10987388
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation.
Lapointe N; Chen H; Qi S; Xu D; Daloze P; Dumont L
Eur Surg Res; 1999; 31(3):259-66. PubMed ID: 10352354
[TBL] [Abstract][Full Text] [Related]
19. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
Sandmann S; Min JY; Meissner A; Unger T
Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391
[TBL] [Abstract][Full Text] [Related]
20. Impaired mechanisms of leukocyte adhesion in vitro by the calcium channel antagonist mibefradil.
Nebe B; Holzhausen C; Rychly J; Urbaszek W
Cardiovasc Drugs Ther; 2002 May; 16(3):183-93. PubMed ID: 12374895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
